3
Medi-Globe Launches mAI Companion® - the World’s First Real‑Time AI Assistant for Pancreatic EUS, Co‑Developed with IHU Strasbourg / Now MDR CE‑Marked and Available for Clinical Use in Europe
more
Stories about Medizinische Behandlung
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
moreGrünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
morePress Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
One documentmoreGrünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
moreServier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
more
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
more30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength
morePress Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
One documentmoreDeutsche Gesellschaft für Chirotherapie und Osteopathie e. V.
Internationally honored: Prof. Dietmar Jürgen Daichendt receives honorary doctorate for pioneering achievements in osteopathy and manual medicine
morePress Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmoreAsklepios Kliniken GmbH & Co. KGaA
Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
more
Letter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
moreAsklepios Kliniken GmbH & Co. KGaA
2Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025
moreEuropäischer Rechnungshof - European Court of Auditors
Läkemedelsbristen är fortfarande en kronisk huvudvärk för EU
moreEuropäischer Rechnungshof - European Court of Auditors
Lääkepula yhä EU:n päänsärkynä
moreEuropäischer Rechnungshof - European Court of Auditors
Medicinmangler er en hovedpine for EU
moreEuropäischer Rechnungshof - European Court of Auditors
(Presskonferens) Kan EU bota bristen på kritiska läkemedel?
Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...
more
Europäischer Rechnungshof - European Court of Auditors
(Ενημέρωση Τύπου) Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας;
Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Pressebriefing) Kan EU afhjælpe kritiske mangler på lægemidler?
Kan EU afhjælpe kritiske mangler på lægemidler? - Online pressebriefing: onsdag den 17. september kl. 10.00 CEST - Offentliggørelse: samme dag kl. 17.00 CEST Den Europæiske Revisionsret inviterer til online pressebriefing vedrørende sin kommende særberetning om EU's foranstaltninger til at sikre tilgængelighed af lægemidler ...
moreServier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
moreUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
morePress release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
One documentmoreGEA expands portfolio for water and wastewater treatment – Flocmix solutions strengthen smart environmental technology
more
Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients
moreTherVacB: Advance Curative Strategy for Chronic Hepatitis B
more- 2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
more Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
moreAxolt Launches Brain Supplement to Combat Post-Pandemic Burnout Crisis
moreFraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
more
123456Next